(Q31407604)

2 July 2017

title

Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis (English)

1 reference

2 July 2017

main subject

visceral leishmaniasis

1 reference

Sundar S

1

1 reference

2 July 2017

Gupta LB

2

1 reference

2 July 2017

Rastogi V

3

1 reference

2 July 2017

Agrawal G

4

1 reference

2 July 2017

Murray HW

5

1 reference

2 July 2017

publication date

1 March 2000

1 reference

Transactions of the Royal Society of Tropical Medicine and Hygiene

2 July 2017

published in

1 reference

2 July 2017

volume

94

1 reference

2 July 2017

issue

2

1 reference

2 July 2017

page(s)

200-204

1 reference

Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years

2 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Treatment of visceral leishmaniasis in children with liposomal amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Successful treatment of visceral leishmaniasis with high-dose amphotericin B diluted in fat emulsion: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Safety and efficacy of Intralipid emulsions of amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Use of Amphotericin B in Drug-Resistant Cases of Visceral Leishmaniasis in North Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Amphotericin versus pentamidine in antimony-unresponsive kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Safety and efficacy of Intralipid emulsions of amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Trial of oral miltefosine for visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Are incremental doses of amphotericin B required for the treatment of visceral leishmaniasis?

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990277-3

7 January 2021

10.1016/S0035-9203(00)90277-3

Identifiers

DOI

1 reference

2 July 2017

1 reference